Bio-Techne Corporation (TECH) Presents at Baird Global Healthcare

Question-and-Answer SessionJames HippelExecutive VP of Finance & CFO Sure. So I mean our key 3 end markets, of course, would be starting large to small, would be our pharma end markets, roughly 30% of our revenue, followed by smaller biotech, which is roughly 20%. And then academia, which is also around 20%, although like roughly a little -- just slightly over half of that's U.S. based and the rest of it is mostly U.S.-based. And when we think about those 3 end markets, starting with pharma, we had predicte ...